Takeda Receives FDA Approval For Three New Type 2 Diabetes Therapies, NESINA (Alogliptin) And Fixed-Dose Combinations OSENI (Alogliptin And Pioglitazone) And KAZANO (Alogliptin And Metformin HCl)
Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda PharmaceuticalsU.S.A., Inc. today announced thatthe United States(U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news
More News: Actos | Diabetes | Diabetes Type 2 | Endocrinology | Food and Drug Administration (FDA) | Fortamet | Metformin | Nutrition | Pharmaceuticals | Sports Medicine